Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2

Therapeutic Drug Monitoring
Akifumi NakamuraTsuyoshi Kondo

Abstract

The authors have previously shown that an early therapeutic response to lamotrigine augmentation therapy is dependent on its plasma concentration and that a plasma lamotrigine concentration of 12.7 μmol/L may be a threshold for a good therapeutic response in treatment-resistant depressive disorder. The present study investigated whether or not an optimal dose of lamotrigine could be predicted from plasma lamotrigine concentration at week 2. The subjects were 37 depressed patients who had already shown insufficient response to at least 3 psychotropics including antidepressants, mood stabilizers, and atypical antipsychotics. The diagnoses were major depressive disorder (n = 15), bipolar I disorder (n = 6), and bipolar II disorder (n = 16). They received augmentation therapy with lamotrigine for 8 weeks. The final doses of lamotrigine were 100 mg/d for 16 subjects who were not taking valproate and 75 mg/d for 21 subjects taking valproate, respectively. Blood sampling was performed at weeks 2 and 8. Plasma concentrations of lamotrigine were measured by high-performance liquid chromatography. There were significant linear relationships between the plasma lamotrigine concentrations at week 2 (x) and those at week 8 (y) for subjects w...Continue Reading

References

Dec 18, 2008·Pharmacoepidemiology and Drug Safety·Arne Reimers
Jan 2, 2009·The British Journal of Psychiatry : the Journal of Mental Science·John R GeddesGuy M Goodwin
Feb 10, 2009·The Journal of Clinical Psychiatry·Marc L M van der LoosUNKNOWN LamLit Study Group
Apr 3, 2012·Biological & Pharmaceutical Bulletin·Yoshiaki YamamotoYoshiyuki Kagawa
May 16, 2012·Journal of Clinical Pharmacy and Therapeutics·B B BrzakovićM Š Prostran

❮ Previous
Next ❯

Citations

Jan 28, 2020·Therapeutic Drug Monitoring·Takeshi SuzukiTsuyoshi Kondo
Jun 1, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stacy M Ku, Ming-Hu Han
Oct 22, 2016·Drugs in R&D·Shery Jacob, Anroop B Nair
Oct 17, 2020·Seizure : the Journal of the British Epilepsy Association·Janthima Methaneethorn, Nattawut Leelakanok

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here